 Taufiq Salahuddin
Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psoriasis | 7 | 2023 | 87 | 1.850 |
Why?
| | Coronary Artery Disease | 7 | 2025 | 680 | 1.360 |
Why?
| | Biological Products | 2 | 2023 | 207 | 1.310 |
Why?
| | Cardiovascular Agents | 1 | 2023 | 157 | 0.760 |
Why?
| | May-Thurner Syndrome | 1 | 2020 | 1 | 0.670 |
Why?
| | Iliac Vein | 1 | 2020 | 11 | 0.660 |
Why?
| | Femoral Vein | 1 | 2020 | 32 | 0.650 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 85 | 0.640 |
Why?
| | Angina, Unstable | 1 | 2019 | 76 | 0.640 |
Why?
| | Thrombolytic Therapy | 1 | 2020 | 137 | 0.610 |
Why?
| | Plaque, Atherosclerotic | 2 | 2017 | 55 | 0.590 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2443 | 0.570 |
Why?
| | Venous Thrombosis | 1 | 2020 | 176 | 0.570 |
Why?
| | Fibrinolytic Agents | 1 | 2020 | 262 | 0.550 |
Why?
| | Coronary Disease | 1 | 2019 | 385 | 0.540 |
Why?
| | Endovascular Procedures | 1 | 2021 | 301 | 0.530 |
Why?
| | Vascular Surgical Procedures | 1 | 2020 | 295 | 0.530 |
Why?
| | Peripheral Arterial Disease | 2 | 2021 | 458 | 0.530 |
Why?
| | Acute Coronary Syndrome | 1 | 2019 | 267 | 0.510 |
Why?
| | Stroke | 3 | 2019 | 1072 | 0.500 |
Why?
| | Heart Failure | 3 | 2025 | 2147 | 0.480 |
Why?
| | Myocardial Infarction | 2 | 2019 | 1021 | 0.470 |
Why?
| | Vascular Calcification | 1 | 2015 | 107 | 0.430 |
Why?
| | Cholesterol | 1 | 2015 | 412 | 0.420 |
Why?
| | Veterans | 1 | 2023 | 1383 | 0.380 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2023 | 92 | 0.370 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 2008 | 0.360 |
Why?
| | Hospitalization | 1 | 2019 | 2075 | 0.330 |
Why?
| | Atrial Fibrillation | 3 | 2016 | 376 | 0.280 |
Why?
| | Ultrasonography, Interventional | 1 | 2025 | 128 | 0.220 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1220 | 0.210 |
Why?
| | Tomography, Optical Coherence | 1 | 2025 | 186 | 0.210 |
Why?
| | Cause of Death | 2 | 2023 | 395 | 0.210 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 711 | 0.200 |
Why?
| | Biological Therapy | 1 | 2023 | 28 | 0.200 |
Why?
| | Humans | 22 | 2025 | 129687 | 0.200 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2023 | 114 | 0.200 |
Why?
| | Quality Indicators, Health Care | 1 | 2025 | 298 | 0.190 |
Why?
| | Women's Health | 1 | 2025 | 364 | 0.190 |
Why?
| | Risk Factors | 10 | 2025 | 9787 | 0.190 |
Why?
| | Freedom | 1 | 2021 | 15 | 0.180 |
Why?
| | Social Class | 1 | 2023 | 259 | 0.180 |
Why?
| | Neutrophils | 2 | 2018 | 1209 | 0.180 |
Why?
| | Limb Salvage | 1 | 2021 | 57 | 0.180 |
Why?
| | Inflammation | 4 | 2018 | 2748 | 0.170 |
Why?
| | Sodium | 1 | 2020 | 205 | 0.160 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2025 | 467 | 0.160 |
Why?
| | Esters | 1 | 2019 | 74 | 0.160 |
Why?
| | Amides | 1 | 2019 | 91 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 4 | 2017 | 2510 | 0.160 |
Why?
| | Cholesterol, HDL | 1 | 2019 | 205 | 0.150 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 1214 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2025 | 567 | 0.150 |
Why?
| | Veterans Health | 1 | 2020 | 179 | 0.150 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2018 | 128 | 0.150 |
Why?
| | Middle Aged | 12 | 2025 | 31165 | 0.150 |
Why?
| | Ischemia | 1 | 2021 | 405 | 0.140 |
Why?
| | Anticholesteremic Agents | 1 | 2019 | 150 | 0.140 |
Why?
| | Sulfhydryl Compounds | 1 | 2019 | 187 | 0.140 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2019 | 541 | 0.140 |
Why?
| | Kidney | 1 | 2025 | 1383 | 0.140 |
Why?
| | United States | 7 | 2025 | 13906 | 0.140 |
Why?
| | Retrospective Studies | 3 | 2025 | 14525 | 0.130 |
Why?
| | Case-Control Studies | 3 | 2019 | 3381 | 0.130 |
Why?
| | Inflammation Mediators | 2 | 2016 | 505 | 0.130 |
Why?
| | Hyperlipidemias | 1 | 2017 | 126 | 0.130 |
Why?
| | Atrial Remodeling | 1 | 2016 | 9 | 0.130 |
Why?
| | Atrial Function, Left | 1 | 2016 | 7 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 900 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1271 | 0.130 |
Why?
| | Aorta | 1 | 2018 | 408 | 0.120 |
Why?
| | Aortitis | 1 | 2015 | 10 | 0.120 |
Why?
| | Prospective Studies | 6 | 2018 | 7145 | 0.120 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2018 | 247 | 0.120 |
Why?
| | Neutrophil Activation | 1 | 2015 | 80 | 0.120 |
Why?
| | Glucose | 1 | 2020 | 1003 | 0.120 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 168 | 0.120 |
Why?
| | Cardiomegaly | 1 | 2016 | 172 | 0.120 |
Why?
| | Multimodal Imaging | 1 | 2015 | 110 | 0.110 |
Why?
| | Aged | 8 | 2025 | 22101 | 0.110 |
Why?
| | Atrial Premature Complexes | 1 | 2014 | 3 | 0.110 |
Why?
| | Female | 15 | 2025 | 68751 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 282 | 0.110 |
Why?
| | Male | 14 | 2025 | 63691 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1368 | 0.110 |
Why?
| | Atherosclerosis | 1 | 2018 | 402 | 0.110 |
Why?
| | DNA Modification Methylases | 1 | 2013 | 13 | 0.110 |
Why?
| | Ventricular Premature Complexes | 1 | 2014 | 36 | 0.110 |
Why?
| | DNA Repair Enzymes | 1 | 2013 | 20 | 0.110 |
Why?
| | Prognosis | 2 | 2019 | 3772 | 0.110 |
Why?
| | Vascular Diseases | 1 | 2016 | 240 | 0.100 |
Why?
| | Human papillomavirus 16 | 1 | 2013 | 34 | 0.100 |
Why?
| | Positron Emission Tomography Computed Tomography | 3 | 2018 | 87 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2025 | 10221 | 0.100 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2013 | 48 | 0.100 |
Why?
| | Self Report | 1 | 2016 | 800 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 311 | 0.090 |
Why?
| | Interleukin-10 | 1 | 2013 | 304 | 0.090 |
Why?
| | Sex Characteristics | 1 | 2015 | 735 | 0.080 |
Why?
| | Biomarkers | 3 | 2016 | 3969 | 0.080 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 297 | 0.080 |
Why?
| | Incidence | 3 | 2025 | 2644 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 2 | 2013 | 2271 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 627 | 0.070 |
Why?
| | Depression | 1 | 2016 | 1322 | 0.070 |
Why?
| | Computed Tomography Angiography | 2 | 2018 | 115 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2025 | 1950 | 0.060 |
Why?
| | Coronary Angiography | 2 | 2018 | 306 | 0.060 |
Why?
| | Hospitals, Veterans | 1 | 2025 | 242 | 0.050 |
Why?
| | Postmenopause | 1 | 2025 | 349 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2018 | 5083 | 0.050 |
Why?
| | Cohort Studies | 3 | 2017 | 5434 | 0.050 |
Why?
| | Stroke Volume | 1 | 2025 | 592 | 0.050 |
Why?
| | Risk Assessment | 2 | 2025 | 3260 | 0.050 |
Why?
| | Electrocardiography | 2 | 2015 | 611 | 0.050 |
Why?
| | Comorbidity | 2 | 2016 | 1551 | 0.050 |
Why?
| | Time Factors | 2 | 2025 | 6545 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2016 | 7064 | 0.040 |
Why?
| | Adult | 6 | 2018 | 35607 | 0.040 |
Why?
| | Neoplasms | 1 | 2013 | 2454 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2739 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2018 | 201 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3084 | 0.030 |
Why?
| | Quality Improvement | 1 | 2025 | 1108 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 271 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 426 | 0.030 |
Why?
| | Ankle Brachial Index | 1 | 2015 | 36 | 0.030 |
Why?
| | Age Distribution | 1 | 2016 | 372 | 0.030 |
Why?
| | Sex Distribution | 1 | 2016 | 359 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 326 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2016 | 205 | 0.030 |
Why?
| | Coronary Vessels | 1 | 2016 | 239 | 0.030 |
Why?
| | Genes, Recessive | 1 | 2013 | 76 | 0.030 |
Why?
| | Echocardiography | 1 | 2016 | 635 | 0.030 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 430 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2014 | 260 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1199 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1500 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 1872 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 316 | 0.020 |
Why?
| | Risk | 1 | 2014 | 855 | 0.020 |
Why?
| | Regression Analysis | 1 | 2013 | 997 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1021 | 0.020 |
Why?
| | Models, Genetic | 1 | 2013 | 592 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3062 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2563 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2015 | 804 | 0.020 |
Why?
| | Survivors | 1 | 2013 | 462 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2013 | 1213 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2724 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4892 | 0.020 |
Why?
| | Genetic Variation | 1 | 2013 | 937 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2062 | 0.010 |
Why?
|
|
Salahuddin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|